1. (Twice Amended) A compound of the formula

or a pharmaceutically acceptable salt thereof wherein:

 R^1 and R^3 are each saturated carbon atoms joined together to form a ring of 6 members in which said carbon atoms [together are 1-3 saturated carbon atoms joined to form a ring of from 5-7 members in which said members] can be unsubstituted or substituted optionally with R_4 ;

R₂ is H; C₁₋₈ alkyl; C₂₋₈ alkyl substituted with OH, NR₅R₆, halogen, C₁₋₄ alkoxy, C₂₋₄ alkoxyC₁₋₄alkoxy, OC(=O)R₇, or C(=O)R₇; C₃₋₇ alkenyl unsubstituted or substituted optionally with OH, NR₅R₆, or C₁₋₄ alkoxy; C₃₋₇ alkynyl unsubstituted or substituted optionally with C₁-C₃alkyl, C₁-C₃halo alkyl, OH, NR₅R₆, or C₁₋₄ alkoxy; C₁₋₃ alkyl substituted with phenyl or R₁₀ either of which can be unsubstituted or substituted optionally with C₁-C₃alkyl, C₁-C₃halo alkyl, OH, (CH₂)_nNR₅R₆, halogen, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, C(=O)R₇, S(=O)_mR₈ or SO₂NR₅R₆, wherein m is 0 - 2 and n is 0 - 2; C₂₋₄ alkoxy substituted optionally with NR₅R₆, halogen, C₁₋₄ alkoxy, or C(=O)R₇; phenyl or R₁₀ either of which can be unsubstituted or substituted optionally with OH, (CH₂)_nNR₅R₆, halogen, C₁₋₄ alkoxy, C(=O)R₇, S(=O)_mR₈ or SO₂NR₅R₆, wherein m is 0 - 2 and n is 0 - 2;

 R_4 is OH; C_{1-4} alkyl unsubstituted or substituted optionally with OH, NR_5R_6 , halogen, C_{1-4} alkoxy or $C(=O)R_7$; C_{1-4} alkoxy; C_{2-4} alkoxy substituted optionally with OH, NR_5R_6 , halogen, C_{1-4} alkoxy or $C(=O)R_7$; NR_5R_6 ; phenyl or R_{10} either of which can be unsubstituted or substituted optionally with OH, $(CH_2)_nNR_5R_6$, halogen, C_{1-4} alkoxy, C_{1-4} haloalkoxy, $C(=O)R_7$, $S(=O)_mR_8$ or $SO_2NR_5R_6$, wherein m is 0 - 2 and n is 0 - 2;

R₅ & R₆ are the same or different and are H; C₁₋₄ alkyl; C₂₋₄ alkyl substituted optionally with OH, halogen, C₁₋₄ alkoxy or C(=O)R₇; C₁₋₄ alkoxy; C₂₋₄ alkoxy substituted optionally with OH, halogen, C₁₋₄ alkoxy or C(=O)R₇; C₃₋₇ alkenyl unsubstituted or substituted optionally with OH, NR₅R₆, or C₁₋₄ alkoxy; C₃₋₇ alkynyl unsubstituted or substituted optionally with OH, NR₅R₆, or C₁₋₄ alkoxy; C₁₋₂alkylC₃₋₅cycloalkyl; C(=0)R₇ or R₅ and R₆ can be joined to form a ring [of 5 or 6 atoms selected from O, S, C or N, such as,] selected from the group consisting of pyrrolidine, oxazolidine, thiomorpholine, thiomorpholine 1,1 dioxide, morpholine, piperazine, [or] and thiazolidine 1,1-dioxide, which can be unsubstituted or substituted optionally on carbon with OH, (=O), halogen, C₁₋₄ alkoxy, C(=O)R₇, C₁₋₆ alkyl, C₁₋₆ alkyl substituted optionally with OH, halogen, C₁₋₄ alkoxy, C(=O)R₇, or on nitrogen with C₁₋₄ alkoxy, C(=O)R₇, S(=O)_mR₈, C₁₋₆ alkyl or C₂₋₆ alkyl substituted optionally with OH, halogen, C₁₋₄ alkoxy, C(=O)R₇ or on sulfur by (=0)_m, wherein m is 0 - 2;

or C(=O)R₉; C₁₋₄ alkoxy; C₂₋₄ alkoxy substituted optionally with OH, NR₅R₆, halogen, C₁₋₄ alkoxy or C(=O)R₉; C₁₋₄ alkoxy; C₂₋₄ alkoxy substituted optionally with OH, NR₅R₆, halogen or C₁₋₄ alkoxy; NR₅R₆; or phenyl or R₁₀ either of which can be unsubstituted or substituted optionally with OH, halogen, C₁₋₃ alkyl, C₁₋₃ haloalkoxy, (CH₂)_nNR₅R₆, S(=0)_mR₈ or SO₂NR₅R₆, wherein n is 0 or 1 and m is 0-2;

 R_8 is C_{1-4} alkyl; C_{2-4} alkyl substituted optionally with OH, NR_5R_6 , halogen, C_{1-4} alkoxy or $C(=O)R_7$;

 R_9 is C_{1-4} alkyl; C_{1-4} alkoxy; amino, C_{1-3} alkylamino, or di- C_{1-3} alkylamino;

R₁₀ is a monocyclic ring system [of 5 or 6 atoms composed of C, N, O, and/or S, such—
as] selected from the group consisting of furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, isothiazole, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, and pyrazine; and

G is $[C(=O) \text{ or}] SO_2$.

(Amended) The compound of Claim 5 wherein: [G is SO₂ and]

 R_4 is OH; C_{1-4} alkoxy; C_{2-4} alkoxy substituted optionally with OH, NR_5R_6 , halogen, C_{1-4} alkoxy or $C(=O)R_7$; or NR_5R_6 ; phenyl, or R_{10} unsubstituted or substituted optionally with OH, $(CH_2)_nNR_5R_6$, halogen, C_{1-4} alkoxy, C_{1-4} haloalkoxy, $C(=O)R_7$, $S(=O)_mR_8$ or $SO_2NR_5R_6$, wherein m is 0 - 2 and n is 0 - 2.

REMARKS

Claims 1-3, 5, 6, 20, 23, 24, 27-29, and 32 are pending. Claims 1 and 6 have been amended.

Claims 1, 7, and 13 are rejected under 35 USC §112, first and second paragraphs. Claim 1 has been amended. R_1 and R_3 are now defined as each being carbon and joined to form a 6 membered ring; the "such as" language has been eliminated and replaced with "selected from the group consisting of" language; and G has been limited to SO_2 . Claims 7 and 13 were cancelled as they would have been essentially commensurate in scope with Claim 1 had they been similarly amended. In view of the above amendments, the Examiner's rejection is moot.